Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera

PFIZER INC

2025-Q3 EPS reported $1.65 revenue$45,022,000,000

Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.
Raises FY2025 adj diluted EPS guidance to $3.00-$3.15 from $2.90-$3.10; reaffirms revenue $61-64B.
Reached landmark agreement with U.S. government on drug pricing; sues Novo Nordisk for tortious interference over Metsera acquisition.
Inclacumab fails Phase 3 THRIVE-131 in sickle cell disease; $1.35B IPR&D charge for 3SBio deal.
Expects ~$7.2B net cost savings by 2027; no share repurchases planned; $7.3B dividends paid YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.